ABSTRACT
Thirty cylindrical, commercially pure, titanium fiber, porous-coated Ti6Al4V implants were inserted press-fit into the proximal humeral portion of 30 sheep humeri to determine the systemic effect of recombinant factor XIII and placenta-derived factor XIII concentrate on bone ingrowth and strength of fixation. For both the recombinant factor XIII and the factor XIII concentrate group, the volume of bone ingrowth and the strength of fixation were higher than for the control specimens. However, the difference was only significant for the factor XIII concentrate group.
Subject(s)
Factor XIII/therapeutic use , Osseointegration/drug effects , Prostheses and Implants , Titanium/therapeutic use , Animals , Antigens, Heterophile/analysis , Biomechanical Phenomena , Bone Remodeling/drug effects , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Factor XIII/administration & dosage , Male , Multivariate Analysis , Porosity , Recombinant Proteins/therapeutic use , Sheep , Titanium/administration & dosageABSTRACT
30 cylindrical commercially pure titanium fiber porous coated Ti6A14V implants were inserted press-fit into the proximal humeral portion of 30 sheep humeri to determine the systemic effect of recombinant factor XIII and placenta-derived factor XIII concentrate on bone ingrowth and on strength of fixation. For both the recombinant factor XIII and the factor XIII concentrate group the volume fraction of bone ingrowth and the strength of fixation was higher when compared with the control specimens. However the difference was only significant for the factor XIII concentrate group.